# Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

> **NCT00231413** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 383 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** HPV 16/18 L1 AS04
- **BIOLOGICAL:** HPV-16/18/31/45 L1 AS04 Formulation 1
- **BIOLOGICAL:** HPV-16/18/31/45 L1 AS04 Formulation 2
- **BIOLOGICAL:** HPV-16/18/31/45 L1 AS04 Formulation 3
- **BIOLOGICAL:** HPV-16/18/31/45 L1 AS04 Formulation 4
- **BIOLOGICAL:** HPV-16/18/31/45 L1 AS04 Formulation 5
- **BIOLOGICAL:** HPV-16/18/31/45 L1 AS04 Formulation 6

## Key facts

- **NCT ID:** NCT00231413
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-04
- **Primary completion:** 2006-03-27
- **Final completion:** 2006-03-27
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00231413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00231413, "Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00231413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*